Safety of Short-Term Trimethoprim-Sulfamethoxazole Use for Uncomplicated Cystitis: A Nationwide Retrospective Cohort Study
Abstract
BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is associated with hypersensitivity and other adverse reactions. East Asian-specific genetic susceptibility may increase severe adverse events, limiting the therapeutic use of TMP-SMX for uncomplicated cystitis in Japan. However, data on its short-term safety in this population are scarce. This study compared the short-term safety of TMP-SMX with fluoroquinolones for the treatment of uncomplicated cystitis using a nationwide Japanese claims database.
METHODS: We conducted a retrospective cohort study using the JMDC Claims Database (2006-2022). We included female outpatients aged ≥ 18 years with acute uncomplicated cystitis who were newly treated with TMP-SMX or fluoroquinolones (levofloxacin, ciprofloxacin, or tosufloxacin). The primary outcome was drug-induced hypersensitivity (anaphylaxis or treatment-requiring rash) within 7 days after the prescription of these drugs. The secondary outcomes included treatment failure, all-cause hospitalization, and other adverse events. Propensity score-overlap weighting was applied to adjust for confounding. Subgroup analyses were stratified by age (< 50 or ≥ 50 years).
RESULTS: Among 50 773 eligible patients (TMP-SMX, 2.1%; fluoroquinolones, 97.9%), the baseline characteristics were well balanced after weighting. The incidence of hypersensitivity did not differ significantly between the groups (0.9% vs. 0.7%; risk difference, 0.3%; 95% confidence interval, -0.3% to 0.8%; p = 0.410). No…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 50 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.